Baidu
map

Clin Otolaryngol:特发性非过敏性鼻炎诊断的鼻适应症测量

2017-07-26 AlexYang MedSci原创

特发性非过敏性鼻炎(i-NAR)是非过敏性鼻炎的一个经常性的起因并且与非特异性症状相关。到现在为止还没有简单直接的方法来建立i-NAR的诊断。目前,i-NAR的诊断基于确定因素的缺失以及皮刺试验中lgE调控过敏证据的缺乏和特异性过敏原血清lgE。鼻声发射的鼻适应症测量评估了鼻粘膜血管生成相关的变形能力。之前的研究已经表明了鼻适应症可能在i-NAR中是异常的。最近,研究人员进行了一个前瞻性的案例-对

特发性非过敏性鼻炎(i-NAR)是非过敏性鼻炎的一个经常性的起因并且与非特异性症状相关。到现在为止还没有简单直接的方法来建立i-NAR的诊断

目前,i-NAR的诊断基于确定因素的缺失以及皮刺试验中lgE调控过敏证据的缺乏和特异性过敏原血清lgE。鼻声发射的鼻适应症测量评估了鼻粘膜血管生成相关的变形能力。之前的研究已经表明了鼻适应症可能在i-NAR中是异常的。

最近,研究人员进行了一个前瞻性的案例-对照研究,研究包括了42名患有慢性鼻炎的病人和21名对照。研究人员发现,在局部充血症状减轻后,i-NAR中的适应症与过敏性鼻炎(AR)组和对照组(n=21)相比显著的增加(p<0.01)。因此,研究人员指出,在局部充血症状减轻后对鼻适应症的测量可以客观的和非侵入性的从过敏性鼻炎中区分i-NAR。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1894618, encodeId=715e18946186e, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sat Aug 26 03:59:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955704, encodeId=bd7e1955e04ab, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Apr 01 08:59:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046861, encodeId=64fe2046861f0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jun 10 11:59:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336746, encodeId=8ca51336e4621, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Fri Jul 28 12:59:00 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1894618, encodeId=715e18946186e, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sat Aug 26 03:59:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955704, encodeId=bd7e1955e04ab, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Apr 01 08:59:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046861, encodeId=64fe2046861f0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jun 10 11:59:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336746, encodeId=8ca51336e4621, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Fri Jul 28 12:59:00 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1894618, encodeId=715e18946186e, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sat Aug 26 03:59:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955704, encodeId=bd7e1955e04ab, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Apr 01 08:59:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046861, encodeId=64fe2046861f0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jun 10 11:59:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336746, encodeId=8ca51336e4621, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Fri Jul 28 12:59:00 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1894618, encodeId=715e18946186e, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sat Aug 26 03:59:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955704, encodeId=bd7e1955e04ab, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Apr 01 08:59:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046861, encodeId=64fe2046861f0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jun 10 11:59:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336746, encodeId=8ca51336e4621, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Fri Jul 28 12:59:00 CST 2017, time=2017-07-28, status=1, ipAttribution=)]

相关资讯

Ann Otol Rhinol Laryn:氟替卡松安特酰胺鼻腔喷雾对具有鼻息肉和常年性变应性鼻炎病人的嗜酸性粒细胞炎症参数的影响

正常T细胞表达激活和分泌的调控(RANTES)和嗜酸性粒细胞趋化因子-2被假设为与鼻粘膜慢性炎症中嗜伊红血球过多有关。最近,有研究人员评估了在具有常年性变应性鼻炎患者和非过敏性/过敏性慢性鼻窦炎鼻息肉(CRSwNP)患者,在鼻腔皮质类固醇治疗之前和之后,RANTES和嗜酸性粒细胞趋化因子-2的粘膜产生情况。研究包括了20名PAR患者,20名非过敏性和20名过敏性CRSwNP患者,以及20名健康对照

J Clin Sleep Med:过敏性和非过敏性鼻炎在阻塞性呼吸暂停综合症中是常见的,但是与疾病严重性无关

一些研究表明了鼻炎是阻塞性呼吸暂停综合症(OSA)的发病机理。最近,有研究人员调查研究了过敏性鼻炎(AR)和非过敏性鼻炎(NAR)对OSA严重程度的影响和流行程度。研究人员通过标准化的多导睡眠描记术确认了240名患有OSA的病人,并用于AR和NAR表现情况的评估,还利用了调查问卷和皮刺试验。另外,研究人员利用卡方检验、变量分析和最小显著差异检验进行了数据比较。还利用了顺序逻辑回归分析评估了OSA的

J Allergy Clin Immun:上皮细胞蛋白组分析表明了干扰素诱导的蛋白质在过敏性鼻炎中的必要作用

季节性过敏性鼻炎(SAR)作为间歇性暴露于季节性花粉中的结果,可以引起鼻子发痒、鼻塞和重复性打喷嚏,并且对生活的品质、工作效率和学校表现具有深远的影响。虽然基因型和环境因素都可能是过敏反应的免疫基础,过敏性鼻炎行管的分子病理阐释仍旧不完全清楚。为了回答这些问题,最近,有研究人员收集了花粉季节时和花粉季节后,来自29名SAR病人和31名对照的鼻上皮刷样本。研究人员进行了基于轨道阱的,倒置免标签定量蛋

BMC Pediatr:婴儿体中增加对随后过敏结果的影响

早期体重的增加与之后过敏结果的关系目前仍旧没有很好的研究。最近,有研究人员调查了体重增加与随后过敏结果的发展的关系。研究的时间为新生儿前36个月,对象为新加坡的一个出生组。在前15个月的重复访问中,研究人员测量了婴儿的体重,并进行了问卷调查,从而确定过敏结果情况。在第18个月和36个月,研究人员对吸入剂和食物过敏原进行皮刺试验(SPTs)。在第18个月,13.5%具有阳性SPT,3.5具有喘息和阳

Int J Pediatr Otorhi:年龄为6-18岁儿童过敏性和非过敏性鼻炎的人口统计学和临床特征预测研究

慢性鼻炎(CR)是儿科患者中是缺课天数、缺课和资源使用率中最常见的起因之一。基于临床的CR、过敏性鼻炎和非过敏性鼻炎常见原因的差异是非常重要的,由于治疗策略差别很大,尤其是在缺乏过敏原敏感性测试的最初医疗设置或设备中。最近,有研究人员基于一个大群体研究并阐释了临床因子,尤其是与AR和NAR相关的面部特性。在一个年龄为6-18岁儿科病人的回顾性分析中,研究人员利用多变量回归方法评估了病人的人口统计学

Pediatr Allergy Immu:青少年中,屋尘螨舌下免疫治疗药片的合用疗效和安全数据

屋尘螨(HDM)呼吸道过敏在儿童和青少年中是一种常见的和让人烦累的疾病。在患有永久性过敏鼻炎的儿童中,HDM过敏原免疫疗法方法还很少。最近,研究人员进行的后分析利用合用数据来评估青少年中(12-17岁)SQ HDM舌下免疫治疗(SLIT)药片的疗效和安全性。2个双盲、安慰剂对照试验分别在北美和日本进行,研究的主体患有HDM过敏性鼻炎,年龄在12岁以上,并随机进行了一年的治疗。在两个试验中主要的评估

Baidu
map
Baidu
map
Baidu
map